Board of Directors

show all hide all

Kim Bjørnstrup

Chairman, independent

Mr. Bjørnstrup has been Chairman of the Board of Veloxis since April 2011. He has more than 20 years of working experience in the pharmaceutical industry. During the past 18 years, he has held various executive positions in the management team of the Octapharma Group and served 8 years as Vice Chairman. Prior to this, he has worked with Coloplast A/S and H. Lundbeck A/S.

Mr. Bjørnstrup is Chairman of the Board of Assistance Personale Service A/S and a Board Member of Xeltis AG (Switzerland). He is trained as a lawyer and holds a Master of Law from Copenhagen University.

Special competencies, important for his capacity as a Board Member, comprise his extensive international biotechnology industry experience and network together with his extensive business development experience.

Dr. Thomas Dyrberg

Deputy Chairman, independent

Dr. Dyrberg has been a Board Member of Veloxis since September 2003. Dr. Dyrberg, Senior Partner, has served at Novo Ventures, Novo A/S, a Danish firm that provides capital for life science companies, since December 2000.

Prior to joining Novo A/S, he served in various positions at Novo Nordisk A/S, a health care company specializing in the treatment of diabetes. Prior to that, he held research positions at the Hagedorn Research Institute, Gentofte, Denmark, and the Scripps Research Institute, La Jolla, California, US.

Dr. Dyrberg received both an MD and a DMSc degree from the University of Copenhagen.

Dr. Dyrberg is the Chairman of the Board of Directors of Lux Biosciences Inc. (US). He currently also serves on the Board of Directors of AlloCure Inc. (US), Delenex Therapeutics AG (Switzerland), Imagen Biotech Inc. (US), Ophthotech Corporation (US).

Special competencies, important for his capacity as a board member of Veloxis, comprise his extensive life-science experience and funding of biotechnological companies.

Anders Götzsche

Board member, independent

Mr. Götzsche has been a Board Member of Veloxis since April 2008. Mr. Götzsche is Executive Vice President and Chief Financial Officer at H. Lundbeck.

After finishing his education Anders Götzsche joined PriceWaterhouseCoopers in 1991. From 1998 he was a Sales Manager with the SAS Institute until 2001, after which he became Director of Group Accounting and Reporting in Group 4 Falck. From 2005 he held the post of Chief Financial Officer for the Berlingske Officin. He joined Lundbeck in 2007.

He holds a Master of Science in Accounting from the University of Southern Denmark (1991) and became a state authorized public accountant in 1997.

Special competencies, important for his capacity as a board member of Veloxis, comprise his experience from international and financial management.

Ed Penhoet

Board member, independent

Mr. Penhoet has been a Board member at Veloxis since July 2011. He joined Alta Partners as a Director in 2000.

As co-founder of Chiron, Mr. Penhoet served as the company's President and Chief Executive Officer from its formation in 1981 until April 1998. He is a member of the Independent Citizens Oversight Committee for the California Institute of Regenerative Medicine (CIRM) and recently served as President of the Gordon and Betty Moore Foundation (US).

Mr. Penhoet was appointed to President Obama's Council of Advisors on Science and Technology (PCAST). PCAST is an advisory group comprising 20 of the nation's leading scientists and engineers who directly advise the President and members of the President's executive staff. PCAST makes policy recommendations in the many areas where understanding of science, technology, and innovation is key to strengthening the U.S. economy. These recommendations help to form policy that works for the American people.

For 10 years prior to founding Chiron, Mr. Penhoet was a faculty member of the Biochemistry Department of the University of California, Berkeley.

Mr. Penhoet is the immediate past Dean of the School of Public Health at the University of California, Berkeley. He is a member of the Institute of Medicine of the National Academy of Sciences and has co-authored more than 50 scientific articles and papers.

Mr. Penhoet serves on the Board of Directors of ChemoCentryx, Inc (US), Immune Design Corp (US), Metabolex, Inc (US), Scynexis, Inc (US), ZymoGenetics, Inc (US).

Special competencies, important for his capacity as a board member of veloxis, comprise his extensive knowledge of pharmaceutical research and development.

Kurt Anker Nielsen

Board member, independent

Mr. Nielsen has been a Board Member of Veloxis since September 2006. Mr. Nielsen is a former CFO and Deputy CEO of Novo Nordisk A/S (1989 to 2000) and co-CEO of Novo A/S (2000 to 2003).

He currently serves as Chairman of the Board of DLH A/S (Dalhoff Larsen & Horneman A/S), is a Board Member of Novo Nordisk Foundation, is Vice Chairman of the Board of Directors of Novozymes A/S, and is a Board Member of Novo Nordisk A/S and Vestas Wind Systems A/S. In Novozymes A/S and Vestas Wind Systems A/S Mr. Nielsen is elected as Audit Committee Chairman. Mr. Nielsen is also Audit Committee member and designated as Audit Committee financial expert in Novo Nordisk A/S. Furthermore he is Chairman of the Board of Collstrup's Mindelegat.

Mr. Nielsen received his Master of Commerce and Business Administration from the Copenhagen Business School in 1972.

Special competencies, important for his capacity as a board member of Veloxis, comprise his working knowledge of the global pharmaceutical industry and his experience in working with accounting, financial and capital markets issues.

Mette Kirstine Agger

Board member, independent

Ms. Agger has been a Board Member of Veloxis since April 2010. Ms. Agger is an Executive Director and Head of LFI Life Science Investments A/S. She joined LFI A/S, a company fully owned by the Lundbeck Foundation, on 1 September 2009.

Prior to this, Ms. Agger was CEO of 7TM Pharma A/S, which she cofounded in late 2000, and from 1996 to 2000 she was part of the management team at NeuroSearch A/S, responsible for business development and licensing.

Ms. Agger is a member of the Board of Directors at Harboe Breweries A/S and Statens Serum Institute, and is Chairman of the Board of Directors of Klifo A/S. Ms. Agger has a Master of Science in Biology from Copenhagen University and an MBA from the Henley Business School, UK.

Ms. Agger's special competencies, which are important for her capacity as a board member, are her extensive biotechnology industry experience and network together with her extensive business development experience and knowledge of intellectual properties within the pharmaceutical sector.